Mobile website
Archive > Volume 29 Issue 7 > 2022,29(7):646-652. DOI:10.3872/j.issn.1007-385X.2022.07.006 Prev Next
Clinical Research
A comparative study of PD-1 antibody plus chemotherapy and antiangiogenic drug plus chemotherapy in the frontline treatment of advanced lung adenocarcinoma
- Article
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
Abstract:
Objective: To study the efficacy and safety of PD-1 antibody plus chemotherapy compared with those of antiangiogenic drug plus chemotherapy in the frontline treatment of advanced lung adenocarcinoma with negative driving genes. Methods: We collected data from 141 patients with unresectable stage ⅢB/ⅢC and Ⅳ lung adenocarcinoma with negative driving genes who were treated in the Fourth Hospital of Hebei Medical University from March 2018 to August 2021, and retrospectively studied the efficacy and safety of PD-1 antibody plus chemotherapy and those of antiangiogenic drug plus chemotherapy in frontline clinical application. The primary outcome measure was the progression-free survival (PFS), and the secondary outcome measures were objective response rate (ORR), disease control rate (DCR) and adverse reactions. Results: All of the 141 patients were included in the survival analysis. The median follow-up time was 13.0 months (95% CI: 12.0-14.0). The ORRs of PD-1 antibody plus chemotherapy group (group A) and antiangiogenic drug plus chemotherapy group (group B) were 33.33% and 27.38% respectively; the DCRs of group A and group B were 98.25% and 89.29%respectively, both with no statistical significance. The median PFSs of group A and group B were 8.4 months (95% CI: 7.3-9.9) and 6.9 months (95% CI: 6.1-7.7) respectively with no statistical significance. The results of subgroup analysis showed that the median PFSs of group A were longer than those of group B for stage ⅢB/ⅢC patients and patients with liver or brain metastasis (all P<0.01). The incidence of adverse reactions in group A and group B were 26.32% and 14.29% respectively, and most of the adverse reactions were grade 1-2. Conclusion: Compared with antiangiogenic drug plus chemotherapy, PD-1 antibody plus chemotherapy had the same efficacy in the frontline treatment of advanced lung adenocarcinoma with negative driving genes and the adverse reactions were tolerable. These two therapies could be standard first-line treatments for advanced lung adenocarcinoma with negative driving genes.
Keywords:
lung adenocarcinoma ; PD-1 antibody ; antiangiogenic drug ; chemotherapy ; prognosis
